You are here: Industry Insights > GlaxoSmithKline

News List

GlaxoSmithKline Gets Expanded FDA Win for Fluarix biospace
January 15, 2018
GSK announced today that it has received approval from the FDA's Biological Evaluation and Research Center
GlaxoSmithKline is Eyeing Pfizer's $15B+ Consumer Biz biospace
January 11, 2018
GlaxoSmithKline Chief Executive Officer Emma Walmsley is eying a big acquisition to spur revenue growth but is making sure that her company will not overpay.
GlaxoSmithKline CEO Replaced 50 Top Managers, Lured Execs From Google, Novartis and Teva biospace
January 11, 2018
GlaxoSmithKline Chief Executive Officer Emma Walmsley is not done reshaping her leadership team as she continues to overhaul the company’s pharmaceutical division
Boehringer Inks €627.5M Deal With GlaxoSmithKline Spinout biospace
December 19, 2017
Boehringer Ingelheim tied up a schizophrenia drug under development by U.K.-based Autifony Limited, a 2011 spinout of GlaxoSmithKline, in a deal that could be worth up to €627.5 million (about $740 million).
FDA approves two-drug regimen, JULUCA for the Treatment of HIV-1 Infection biospace
November 23, 2017
HIV patients have a new maintenance drug in their arsenal of medication.
Merck, GlaxoSmithKline face hepatitis A vaccine shortage amid U.S. outbreaks fiercepharma
November 15, 2017
Since March, the CDC’s Division of Viral Hepatitis has identified hepatitis A outbreaks in several cities in California, Michigan and Utah, especially among people who are homeless and people who use drugs.
Chutes & Ladders—GlaxoSmithKline CSO Vallance out, Hal Barron in fiercebiotech
November 13, 2017
Please send the good word—or the bad—from your shop to Angus Liu (email) and we will feature it here at the end of each week.
GlaxoSmithKline Poaches New CSO From Google's Calico biospace
November 10, 2017
GlaxoSmithKline Chief Executive Officer Emma Walmsley continues to shape her executive team. After poaching Luke Miels from AstraZeneca,
GlaxoSmithKline R&D chief Vallance to leave for government job: FT fiercebiotech
November 06, 2017
GlaxoSmithKline’s long-standing president of R&D, Patrick Vallance, is said to be standing down.
GlaxoSmithKline Pharma Q2 net up 32 per cent at Rs 130 crs expressbpd
October 26, 2017
Drug firm GlaxoSmithKline Pharmaceuticals today reported a 31.83 per cent rise in standalone net profit to Rs 130.32 crore for the second quarter ended September 30, 2017.

Previous page 1 2 3 4 5 6 7 8 9 10 11 Next page